Manufacturer
L.B.S. LABS LTD PART
Contents
Furosemide
Indication
Acute pulmonary oedema, Oedema associated with heart failure.
Instruction
Administer via IM/slow IV injection/slow IV infusion.
Drug interaction
May increase nephrotoxicity of cephalosporins (e.g. cefalotin), NSAIDs. May increase ototoxicity of aminoglycoside, ethacrynic acid, other ototoxic drugs. Reduced serum level w/ aliskiren. May increase hypotensive effect of ACE inhibitors or angiotensin II receptor antagonists. Increased risk of hyperkalaemia w/ K-sparing diuretics. Increased risk of cardiotoxicity w/ cardiac glycosides, antihistamines. May reduce serum level of lithium. May antagonise hypoglycaemic effect of antidiabetics. Increased hypotensive effect w/ MAOIs. Increased hyponatraemia w/ carbamazepine. Reduced natriuretic and hypotensive effect w/ indometacin. Diminished diuretic effect w/ salicylates.
L.B.S. LABS LTD PART
Contents
Furosemide
Indication
Acute pulmonary oedema, Oedema associated with heart failure.
Instruction
Administer via IM/slow IV injection/slow IV infusion.
Drug interaction
May increase nephrotoxicity of cephalosporins (e.g. cefalotin), NSAIDs. May increase ototoxicity of aminoglycoside, ethacrynic acid, other ototoxic drugs. Reduced serum level w/ aliskiren. May increase hypotensive effect of ACE inhibitors or angiotensin II receptor antagonists. Increased risk of hyperkalaemia w/ K-sparing diuretics. Increased risk of cardiotoxicity w/ cardiac glycosides, antihistamines. May reduce serum level of lithium. May antagonise hypoglycaemic effect of antidiabetics. Increased hypotensive effect w/ MAOIs. Increased hyponatraemia w/ carbamazepine. Reduced natriuretic and hypotensive effect w/ indometacin. Diminished diuretic effect w/ salicylates.
Inquiry - H-Mide Injection